CLAIMS

1. Use of Anifrolumab in the manufacture of a medicament for treating lupus nephritis (LN) in a subject in need thereof, wherein a first dose of 1050 to 1200 mg of anifrolumab is to be subcutaneously administered to the subject once every 4 weeks (Q4W) at least 3 times before administration of a second dose of anifrolumab, wherein the first dose is higher than the second dose, wherein the medicament reduces lupus nephritis (LN) disease activity in the subject.
2. The use of claim 1, wherein the first dose is 1100 to 1190 mg.
3. The use of claim 2, wherein the first dose is 1150 to 1160 mg.
4. The use of claim 3, wherein the first dose is 1150 mg or 1155 mg.
5. The use of claim 1, wherein the first dose is to be administered in a volume of about 8 ml.
6. The use of claim 1, wherein the first dose is to be administered in a volume of about 7.7 ml.
7. Use of Anifrolumab in the manufacture of a medicament for treating LN in a subject in need thereof, wherein a first dose of about 900 mg of anifrolumab is to be intravenously administered to the subject once every 4 weeks (Q4W) at least 3 times before administration of a second dose of anifrolumab, wherein the first dose is higher than the second dose, and wherein the medicament reduces lupus nephritis (LN) disease activity in the subject.
8. The use of any of the preceding claims, wherein the second dose is to be administered subcutaneously.
9. The use of claim 8, wherein the second dose is >105 mg and ≤135 mg.
10. The use of claim 9, wherein the second dose is about 120 mg.
11. The use of claim 8 or 9, wherein the second dose is to be administered once per week.
12. The use of any of claims 1 to 7, wherein the second dose is to be administered intravenously.
13. The use of claim 12, wherein the second dose is 300 mg anifrolumab, optionally wherein the second dose is to be administered Q4W.